🧬 Généthon was created in 1990 with a focus on gene therapy research for rare genetic diseases.
💡 Revah discusses the challenges of financing development for rare diseases and the need for equity in distribution.
🏭 Généthon is working on improving bioprocessing and reducing the cost of production for gene therapies.
🤝 The organization collaborates with partners in various fields to advance their research.
⚙️ Exciting developments include producing AAV in plants and using artificial intelligence to optimize bioreactors.
❌ The industry faces challenges such as improving the full-to-empty ratio of virus capsids.
❗️ Revah comments on the Pfizer incident and assures that Généthon is closely monitoring safety in their own clinical trial.
Introduction:
This article features an interview with Frédéric Revah, CEO of Généthon, a non-profit organization focused on gene therapy research. Revah discusses the history, present, and future of Généthon, particularly in the context of its research in muscular dystrophy. The interview explores the challenges and progress in gene therapy for rare genetic diseases, the impact of rare disease research on more common diseases, and the strategies employed by Généthon to improve bioprocessing and reduce production costs.
- Généthon was created by the French Muscular Dystrophy Association in 1990 with a focus on research in gene therapy, particularly for Duchenne muscular dystrophy (DMD).
- Généthon has transitioned from a research institute to a biotech organization, with a pipeline of therapies and industrial partnerships, under the leadership of Frédéric Revah.
- The financing and market challenges for gene therapy in rare diseases require a balance between the needs of patients and the resources available.
- Research in rare genetic diseases also contributes to the development of technologies and approaches for more common diseases, making it a public health issue.
- Généthon is working on improving bioprocessing through partnerships and collaborations, including the production of AAV in plants and the systematic genetic engineering of production cells.
Conclusion:
The interview with Frédéric Revah highlights the progress and challenges in gene therapy research, specifically for rare genetic diseases. Généthon’s focus on muscular dystrophy and its efforts to improve bioprocessing and reduce production costs demonstrate the organization’s commitment to advancing gene therapies and making them more accessible for patients. Généthon’s work also highlights the importance of rare disease research in contributing to the development of therapies for more common diseases.
